Alzheimer's Disease Annual U.S. Costs Surpass Combined Cancer and Heart Disease Totals, Driven by Medicare Enrollment Growth

CMS National Health Expenditure data and Alzheimer's Association 2024 projections document the shift: total costs reached $345 billion, with projections hitting $1.1 trillion by 2050 under current incidence rates of 6.9 million Americans over 65. Medicare spending on dementia-related claims grew 4.8 percent annually from 2016-2022, outpacing overall program growth. The structure of fee-for-service reimbursement and long-term care coverage creates direct fiscal exposure for federal and state budgets.

Primary records from CMS and Congressional Budget Office show Alzheimer's now accounts for 18 percent of Medicare Part A and B outlays for beneficiaries over 75. State Medicaid programs face parallel pressure through nursing facility payments, with 2023 data indicating 52 percent of long-stay residents carry dementia diagnoses. This trajectory directly widens structural deficits absent changes to eligibility or benefit design.

The incentive structure favors continued expansion of institutional care over community-based alternatives, locking in higher per-capita expenditures. Without adjustments to reimbursement formulas or prevention protocols, the cost trajectory remains linear with demographic aging rather than responsive to policy levers.

CBO baseline models project Medicare spending on dementia care will require either payroll tax increases, benefit reductions, or debt issuance by 2035 to maintain current coverage levels.